SGLT2 inhibitors in hemodialysis or peritoneal dialysis patients: rationale and state-of-the art Abstract. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of end-stage kidney disease (ESKD), cardiovascular events, and all-cause morta

SGLT2 inhibitors in hemodialysis or peritoneal dialysis patients: rationale and state-of-the art
#OpenAccess
Full text 👉https://buff.ly/VrurlWC

#Cardiovascular
#Haemodialysis
#PeritonealDialysis
#PeritonealMembrane
#SGLT2Inhibitors
#Nephrology
#KidneyCare
#nephsky
#medsky